APA (7th ed.) Citation

Padovan, M., Eoli, M., Pellerino, A., Rizzato, S., Caserta, C., Simonelli, M., . . . Lombardi, G. (2021). Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). Cancers, 13(11), 2773. https://doi.org/10.3390/cancers13112773

Chicago Style (17th ed.) Citation

Padovan, Marta, et al. "Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)." Cancers 13, no. 11 (2021): 2773. https://doi.org/10.3390/cancers13112773.

MLA (9th ed.) Citation

Padovan, Marta, et al. "Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)." Cancers, vol. 13, no. 11, 2021, p. 2773, https://doi.org/10.3390/cancers13112773.